Pricing Log in Create free account
Saturday 17 October 2026 Export MRK’s income statement to Excel — free account

Merck & Co., Inc.

MRK Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.

145.95 0.76 +0.52%
Market cap
$358.2B
P/E
117×
Fwd P/E
53.9×
Dividend yield
2.33%
F-score
4/9
Altman Z
3.77
Beneish M
−2.27
Dividend safety
74/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Merck & Co., Inc. (MRK) Price to free cash flow

Alert me on Price to free cash flow

As of 16 October 2026, Merck & Co., Inc. (MRK) trades at a price to free cash flow of 22.4×. Over the past ten years it has ranged from 10.9× (May 2025) to 487× (December 2020); the current reading is higher than 44% of that period. That is above the Drug Manufacturers General industry median of 16.5× and above the Healthcare sector median of 20.2×.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 21.3× 53.08%
FY2024 13.9× (55.70%)
FY2023 31.4× 64.22%
FY2022 19.1× (14.40%)
FY2021 22.4× (63.91%)
FY2020 61.9× 53.47%
FY2019 40.4× 72.62%
FY2018 23.4× (27.16%)
FY2017 32.1× 77.14%
FY2016 18.1× 43.70%

Quarterly newest first

Period Price to free cash flow Change
Jun 2026 19.8× (6.21%)
Mar 2026 21.1× (1.13%)
Dec 2025 21.3× 32.78%
Sep 2025 16.0× 18.90%
42 more quarters

Against its own ten years

Low 10.9× High 487×
Ten-year median 23.4×
Current reading's percentile 44

Price to free cash flow against peers

Company Price to free cash flow
GILD Gilead Sciences, Inc. compare 15.0×
PFE Pfizer Inc. compare 16.5×
NVS Novartis AG compare 18.9×
MRK Merck & Co., Inc. 22.4×
NVO Novo Nordisk A/S compare 22.6×
AMGN Amgen Inc. compare 24.0×
JNJ Johnson & Johnson compare 27.1×
ABBV AbbVie Inc. compare 27.7×
AZN AstraZeneca PLC compare 40.9×
Drug Manufacturers General industry median 16.5×
Healthcare sector median 20.2×
Market median 14.2×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on MRK